Breast Cancer News and Research

Latest Breast Cancer News and Research

1.3 million cancer deaths in 2012 in the EU: Report

New research released this Wednesday shows that almost 1.3 million people will die of cancer in the European Union this year, but death rates from the disease are on a steady decline.

1 Mar 2012

SIR to showcase latest minimally invasive treatments at 37th annual meeting

Health, science and medical reporters are invited to register now for the Society of Interventional Radiology's 37th Annual Scientific Meeting March 24 at Moscone Center (North), San Francisco, Calif. The meeting's theme, "IR Evidence," was chosen to focus on the results of care-changing investigations that showcase research into minimally invasive treatments that provide treatment options, advance patient care and improve quality of life.

1 Mar 2012

Loss of STAT1 transcription factor causes breast cancer development

Breast cancer represents about a fifth of all cancers diagnosed in women. The reasons for the rapid progression of the disease remain relatively poorly understood but recent work in the group of Veronika Sexl at the University of Veterinary Medicine, Vienna has pointed the finger strongly at loss or inactivation of the transcription factor STAT1.

1 Mar 2012

Bayer receives FDA approval for lower dose formulation of ANGELIQ

Bayer HealthCare Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a lower dose formulation of ANGELIQ (drospirenone and estradiol) tablets to treat moderate to severe vasomotor symptoms due to menopause in women who have a uterus.

29 Feb 2012

On-site pathology evaluations cut operating time, reduce costs of breast cancer care

Nearly one in three women who have breast cancer surgery will need to return to the operating room for additional surgery after the tumor is evaluated by a pathologist.

29 Feb 2012

Cancer survival rates on the rise in Northern Ireland

Despite the rising incidence of cancer in Northern Ireland, the number of people surviving the disease in the country is increasing significantly year on year.

29 Feb 2012

SWHR, NAMS encourage women to understand benefits and risks of hormone therapy

Hormone therapy (HT) remains the most effective treatment available for menopausal hot flashes and night sweats. The Society for Women's Health Research (SWHR) and The North American Menopause Society (NAMS) encourage women to understand the benefits and risks of hormone therapy in order to decide if this therapy is right for them.

29 Feb 2012

EpiCept fourth quarter revenue decreases to $0.2 million

EpiCept Corporation today announced operating and financial results for the fourth quarter and full year ended December 31, 2011, and provided an update on the Company's key business initiatives.

29 Feb 2012

Quitting hormone therapy can lead to breast tumor regression

As soon as women quit hormone therapy, their rates of new breast cancer decline, supporting the hypothesis that stopping hormones can lead to tumor regression, according to a report e-published in Cancer Epidemiology, Biomarkers, & Prevention.

29 Feb 2012

Maturitas publishes EMAS' clinical guide on SERMs against postmenopausal osteoporosis

Elsevier, a world-leading provider of scientific, technical and medical information products and services, announced today the publication of an important clinical guide from the European Menopause and Andropause Society (EMAS) in the February issue of Maturitas.

29 Feb 2012

XL888 inhibitor can prevent vemurafenib resistance in melanoma patients

Researchers at Moffitt Cancer Center in Tampa, Fla., and colleagues in California have found that the XL888 inhibitor can prevent resistance to the chemotherapy drug vemurafenib, commonly used for treating patients with melanoma.

29 Feb 2012

FDA panel schedules review for U-Systems' somo•v ABUS system

U-Systems, the leader in automated breast ultrasound, today announced the somo•v Automated Breast Ultrasound (ABUS) system has been scheduled for review by the Radiological Devices Panel of the U.S. Food & Drug Administration (FDA) on April 11, 2012.

28 Feb 2012

Study finds subtle cognitive deficits in women treated with CMF chemotherapy

Dutch investigators have reported that women who received CMF chemotherapy (a combination regimen including the drugs cyclophosphamide, methotrexate, and 5-fluorouracil) for breast cancer between 1976 and 1995 scored worse on cognitive tests than women who never had cancer.

28 Feb 2012

FDA grants 510(k) clearance for Ventana Ki-67 image analysis algorithm

Ventana Medical Systems, Inc., a member of the Roche Group, received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the VENTANA Companion Algorithm Ki-67 (30-9) image analysis application used with the VENTANA iScan Coreo Au scanner running VIRTUOSO software.

27 Feb 2012

First patients in Germany treated with Delcath Hepatic CHEMOSAT Delivery System

Delcath Systems, Inc., announced today that the first patients in Germany have been treated with the Delcath Hepatic CHEMOSAT Delivery System at the Johann Wolfgang Goethe University Hospital, a premier European cancer treatment and research center located in Frankfurt. The cases were treated as part of the initial launch and training agreement the Company announced with the hospital in December 2011.

27 Feb 2012

Two-target approach may effectively stop pancreatic cancer metastasis

Simultaneous targeting of two different molecules in cancer is an effective way to shrink tumors, block invasion, and stop metastasis, scientists at the University of California, San Francisco (UCSF) have found—work that may improve the effectiveness of combination treatments that include drugs like Avastin.

27 Feb 2012

UCSF: 1-2 punch blocks tumor growth, invasion and metastasis

Simultaneous targeting of two different molecules in cancer is an effective way to shrink tumors, block invasion, and stop metastasis, scientists at the University of California, San Francisco (UCSF) have found-work that may improve the effectiveness of combination treatments that include drugs like Avastin.

24 Feb 2012

Women over 40 have better prognosis after mammography screening

Based on a study of nearly 2,000 breast cancer patients, researchers at the Swedish Cancer Institute in Seattle say that, in women between the ages of 40 and 49, breast cancers detected by mammography have a better prognosis. The study appears in the March issue of Radiology.

23 Feb 2012

New kind of on-off switch for cortisol release in the brain discovered

After we sense a threat, our brain center responsible for responding goes into gear, setting off a chain of biochemical reactions leading to the release of cortisol from the adrenal glands.

23 Feb 2012